Novartis

News Hour: Novartis announced the launch of an innovative technology-based healthcare program called SMS for Life 2.0 in Kaduna State, Nigeria. The program aims to increase the availability of essential medicines and improve care for patients...

News Hour: Novartis announced that it has entered into a definitive agreement for the acquisition of Ziarco Group Limited, a privately held company focused on the development of novel treatments in dermatology. This acquisition would add...

News Hour: Novartis announced today that Rwanda is the third country to sign a memorandum of understanding with Novartis Access after Kenya and Ethiopia. This agreement contributes to the strategy of the Rwandan government to increase...

News Hour: Novartis will present data demonstrating the latest advancements from its oncology research program at the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, San Diego, December 3-6, and the San Antonio Breast...

News Hour: New data showing Cosentyx® (secukinumab) delivers sustained improvements in the signs and symptoms of psoriatic arthritis (PsA) over three years – including patient-reported pain. These findings were presented at the 2016 Annual Meeting of...

News Hour: Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving...

News Hour: Psoriasis is a common, non-contagious, autoimmune disease that affects up to 3% of the world’s population.Novartis presented new findings from the largest global survey to date of people with psoriasis, showing many do not...

News Hour: Cosentyx is a fully human monoclonal antibody that selectively neutralizes IL-17A. Research suggests that IL-17A may play an important role in driving the body’s immune response in psoriasis, ankylosing spondylitis (AS) and psoriatic arthritis...

News Hour: Novartis announced  that the US Food and Drug Administration (FDA) has granted three simultaneous approvals for the expanded use of Ilaris® (canakinumab) to treat three rare and distinct types of Periodic Fever Syndromes. Ilaris...

News Hour: Zykadia may cause stomach upset and intestinal problems in most patients, including diarrhea, nausea, vomiting and stomach-area pain. Novartis announced top-line results from its Phase III ASCEND-4 clinical study for Zykadia® (ceritinib) in patients...